Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-02-23
DOI
10.3389/fimmu.2021.636081
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
- (2020) Jackson G. Egen et al. IMMUNITY
- Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors
- (2020) Brendan T. Parr et al. ACS Medicinal Chemistry Letters
- Supplementation of L‐arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy
- (2020) Yusuke Satoh et al. CANCER SCIENCE
- A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma
- (2020) David A. Reardon et al. INVESTIGATIONAL NEW DRUGS
- Advances in the discovery and development of selective heme-displacing IDO1 inhibitors
- (2020) Lijun Sun Expert Opinion on Drug Discovery
- Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy
- (2020) Jackie E. Bader et al. MOLECULAR CELL
- Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
- (2020) Luis Felipe Campesato et al. Nature Communications
- IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression
- (2020) Ahmed Sadik et al. CELL
- Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
- (2020) Magdalena Konieczny et al. JOURNAL OF MEDICINAL CHEMISTRY
- IDO Expression in Cancer: Different Compartment, Different Functionality?
- (2020) Annabel Meireson et al. Frontiers in Immunology
- Indoleamine and tryptophan 2,3-dioxygenases as important future therapeutic targets
- (2020) Ana Dolšak et al. PHARMACOLOGY & THERAPEUTICS
- Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
- (2019) Michael Platten et al. NATURE REVIEWS DRUG DISCOVERY
- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
- (2019) Kyung Hae Jung et al. CLINICAL CANCER RESEARCH
- Development of the Inhibitors that Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles
- (2019) Guzik et al. MOLECULES
- The landscape of cancer cell line metabolism
- (2019) Haoxin Li et al. NATURE MEDICINE
- Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
- (2019) Maisa C. Takenaka et al. NATURE NEUROSCIENCE
- Tryptophan Metabolic Pathways and Brain Serotonergic Activity: A Comparative Review
- (2019) Erik Höglund et al. Frontiers in Endocrinology
- Discovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors
- (2019) Wangyang Tu et al. ACS Medicinal Chemistry Letters
- Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment
- (2019) Juliane Günther et al. Frontiers in Immunology
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Echoes of a failure: what lessons can we learn?
- (2019) Vernon K Sondak et al. LANCET ONCOLOGY
- Adding indoximod to hypofractionated radiotherapy with anti-PD-1 checkpoint blockade enhances early NK and CD8+ T cell-dependent tumor activity
- (2019) Tsubasa Watanabe et al. CLINICAL CANCER RESEARCH
- Structural Basis of Inhibitor Selectivity in Human Indoleamine 2,3-Dioxygenase 1 and Tryptophan Dioxygenase
- (2019) Khoa N. Pham et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy
- (2019) Hongjun Zhang et al. ACS Medicinal Chemistry Letters
- Metabolomic adaptations and correlates of survival to immune checkpoint blockade
- (2019) Haoxin Li et al. Nature Communications
- Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma
- (2019) Soudabeh Rad Pour et al. Scientific Reports
- The therapeutic potential of targeting tryptophan catabolism in cancer
- (2019) Christiane A. Opitz et al. BRITISH JOURNAL OF CANCER
- Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers
- (2019) Delia Hoffmann et al. Cancer Immunology Research
- Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors
- (2019) Florence Schramme et al. Cancer Immunology Research
- Tumor-Repopulating Cells Induce PD-1 Expression in CD8 + T Cells by Transferring Kynurenine and AhR Activation
- (2018) Yuying Liu et al. CANCER CELL
- A patent review of IDO1 inhibitors for cancer
- (2018) Jae Eun Cheong et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Regulation of the Immune Response by the Aryl Hydrocarbon Receptor
- (2018) Cristina Gutiérrez-Vázquez et al. IMMUNITY
- Hypothesis kynurenic and quinolinic acids: The main players of the kynurenine pathway and opponents in inflammatory disease
- (2018) Abdulla A.-B. Badawy MEDICAL HYPOTHESES
- Leucine competes with kynurenine for blood-to-brain transport and prevents lipopolysaccharide-induced depression-like behavior in mice
- (2018) Adam K. Walker et al. MOLECULAR PSYCHIATRY
- Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
- (2018) Todd A Triplett et al. NATURE BIOTECHNOLOGY
- Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2)
- (2018) Zhonghua Pei et al. ACS Medicinal Chemistry Letters
- Single cell analysis of kynurenine and System L amino acid transport in T cells
- (2018) Linda V. Sinclair et al. Nature Communications
- Abstract 1701: EPL-1410, a novel fused heterocycle based orally active dual inhibitor of IDO1/TDO2, as a potential immune-oncology therapeutic
- (2018) Srinivas Gullapalli et al. CANCER RESEARCH
- Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
- (2018) Bruno Gomes et al. MOLECULAR CANCER THERAPEUTICS
- Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
- (2018) Alexander J. Muller et al. Seminars in Immunopathology
- Current state on tryptophan 2,3-dioxygenase inhibitors: a patent review
- (2018) Arina Kozlova et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Hypertryptophanemia due to tryptophan 2,3-dioxygenase deficiency
- (2017) Patrick Ferreira et al. MOLECULAR GENETICS AND METABOLISM
- Abstract LB-085: RG70099: A novel, highly potent dual IDO1/TDO inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment
- (2016) Gabor Gyulveszi et al. CANCER RESEARCH
- The end of the road for the tryptophan depletion concept in pregnancy and infection
- (2016) A. A.- B. Badawy et al. CLINICAL SCIENCE
- Insights into the mechanism of inhibition of tryptophan 2,3-dioxygenase by isatin derivatives
- (2016) Georgios Pantouris et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- The Safety and Regulatory Process for Amino Acids in Europe and the United States
- (2016) Ashley Roberts JOURNAL OF NUTRITION
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
- (2016) Caroline Jochems et al. Oncotarget
- Stress Kinase GCN2 Controls the Proliferative Fitness and Trafficking of Cytotoxic T Cells Independent of Environmental Amino Acid Sensing
- (2016) Lee-Ann Van de Velde et al. Cell Reports
- The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas
- (2016) Jana K. Sonner et al. OncoImmunology
- Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma
- (2015) A. Masaki et al. CLINICAL CANCER RESEARCH
- Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway
- (2015) Amy B. Dounay et al. JOURNAL OF MEDICINAL CHEMISTRY
- Re-examination of Dietary Amino Acid Sensing Reveals a GCN2-Independent Mechanism
- (2015) David E. Leib et al. Cell Reports
- Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
- (2015) Nicolas van Baren et al. Frontiers in Immunology
- Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival
- (2015) Debbie M Ferns et al. OncoImmunology
- Amino acids inhibit kynurenic acid formation via suppression of kynurenine uptake or kynurenic acid synthesis in rat brain in vitro
- (2015) Airi Sekine et al. SpringerPlus
- Keeping the eIF2 alpha kinase Gcn2 in check
- (2014) Beatriz A. Castilho et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment
- (2014) Yuko Tanizaki et al. CANCER SCIENCE
- The SOCS3-Independent Expression of IDO2 Supports the Homeostatic Generation of T Regulatory Cells by Human Dendritic Cells
- (2014) S. Trabanelli et al. JOURNAL OF IMMUNOLOGY
- Aryl hydrocarbon receptor control of a disease tolerance defence pathway
- (2014) Alban Bessede et al. NATURE
- Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
- (2014) I. Theate et al. Cancer Immunology Research
- AhR-Mediated, Non-Genomic Modulation of IDO1 Function
- (2014) Maria Teresa Pallotta et al. Frontiers in Immunology
- Tryptophan-Catabolizing Enzymes – Party of Three
- (2014) Helen J. Ball et al. Frontiers in Immunology
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
- (2012) L. Pilotte et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
- (2012) Richard Metz et al. OncoImmunology
- IDO Induces Expression of a Novel Tryptophan Transporter in Mouse and Human Tumor Cells
- (2011) J. D. Silk et al. JOURNAL OF IMMUNOLOGY
- Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators
- (2011) Eduard Dolušić et al. JOURNAL OF MEDICINAL CHEMISTRY
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
- (2011) Maria T Pallotta et al. NATURE IMMUNOLOGY
- Kynurenine metabolism in health and disease
- (2010) Lukasz R. Kolodziej et al. AMINO ACIDS
- An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
- (2010) J. D. Mezrich et al. JOURNAL OF IMMUNOLOGY
- Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
- (2010) H. K. Koblish et al. MOLECULAR CANCER THERAPEUTICS
- Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism
- (2010) N. T. Nguyen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tryptophan Deprivation Induces Inhibitory Receptors ILT3 and ILT4 on Dendritic Cells Favoring the Induction of Human CD4+CD25+ Foxp3+ T Regulatory Cells
- (2009) M. Brenk et al. JOURNAL OF IMMUNOLOGY
- Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice
- (2009) Masaaki Kanai et al. Molecular Brain
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now